Risperidone
Brand names: Risperdal, Risperdal Consta (LAI)
Risperidone is a second-generation (atypical) antipsychotic used for schizophrenia, acute mania in bipolar disorder, and short-term treatment of persistent aggression in certain situations.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a potent antagonist at dopamine D2 and serotonin 5-HT2A receptors, with additional alpha-adrenergic and histaminergic blockade, reducing positive psychotic symptoms while raising prolactin.
Prescribing in practice
- It increases the risk of stroke and death when used for behavioural and psychological symptoms in elderly people with dementia, so such use must be short-term, justified and reviewed.
- It commonly raises prolactin, which can cause galactorrhoea, sexual dysfunction and menstrual disturbance, and is dose-dependently associated with extrapyramidal side effects.
- Postural hypotension can occur on initiation and dose titration, particularly in the elderly.
Monitoring
Monitor weight, fasting glucose or HbA1c, lipids, blood pressure, prolactin-related symptoms and emergence of extrapyramidal effects at baseline and regularly.
Counselling the patient
- Report breast changes, milk production, sexual or menstrual problems, or muscle stiffness and abnormal movements.
- Stand up slowly when starting treatment to reduce dizziness.
- Attend regular physical-health checks and do not stop the medicine abruptly without advice.
Evidence & guidelines
NICE lists risperidone among first-line antipsychotic options for schizophrenia and bipolar mania, with explicit caution about stroke risk in dementia.
Reference: NICE NG117; BAP Antipsychotic Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185